Skip to main content

Table 4 In-hospital management in secondary care hospitals

From: Improved treatment and prognosis after acute myocardial infarction in Estonia: cross-sectional study from a high risk country

  Year 2001 Year 2007 Year 2011 P value for trend
n = 213 n = 360 n = 363
% % %
Medications     
 Aspirin 88.3 86.4 85.7 0.383
 P2Y12-receptor inhibitors 0 10.6 26.4 <0.001
 Anticoagulants 85.4 92.8 95.0 <0.001
 Glycoprotein IIb/IIIa inh. 0.5 3.1 5.2 0.003
 Betablockers 76.1 77.8 73.0 0.384
 Nitrates 96.7 85.6 78.8 <0.001
 ACEi/ARB 37.1 62.2 55.9 <0.001
 Statins 5.6 30.8 49.0 <0.001
Cardiac catheterization 0 6.7 18.5 <0.001
Revascularization 0 4.2 14.3 <0.001
 PCI 0 4.2 14.3 <0.001
 CABG 0 0 0 -
Echocardiography 52.1 51.9 50.7 0.735
Referred to a tertiary care hospital 5.8 24.8 40.1 <0.001
Treatment for STEMI n = 127 n = 185 n = 161  
Reperfusion for STEMI 44.1 34.1 37.9 0.251
 Thrombolysis 44.1 34.1 29.2 0.008
 Primary PCI 0 0 8.7 -
Treatment for NSTEMI n = 86 n = 175 n = 202  
 PCI 0 4.6 10.4 0.002
 CABG 0 0 0 -
 Referred to a tertiary care hospital 5.8 10.3 28.2 <0.001
  1. Anticoagulants – low molecular weight heparins/unfractionated heparin, fondaparinux, ACEi angiotensin-converting enzyme inhibitors, ARB angiotensin II receptor blockers, P2Y12-receptor inhibitors – ticlopidine/clopidogrel/ticagrelol, CABG coronary artery bypass grafting, PCI percutaneous coronary intervention, STEMI ST-segment elevation myocardial infarction, NSTEMI non-ST-segment elevation myocardial infarction